**[Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease](https://www.zgt.nl/media/20459/krens-panitumumab-2018.pdf" \o "Krens panitumumab 2018.pdf)**

Krens LL, Baas JM, Guchelaar HJ, Gelderblom H

Cancer Chemother Pharmacol 2018;81(1):179-182

[**‘Highs and lows’ van medicinale cannabis**](https://www.pil-nascholing.nl/tijdschrift/editie/artikel/t/highs-and-lows-van-medicinale-cannabis)**’**

Van der Elst KCM, [Brummelhuis-Visser P](https://www.zgt.nl/patienten-en-bezoekers/medisch-specialisten/brummelhuis-visser-p/?currentpageid=2847&specialisme=-1&functie=-1&letter=&q=brumm), van Roon E.N.

PIL 2018:editie 1 (maart).

[**Invasive Candidiasis in the Elderly: Considerations for Drug Therapy**](https://www.zgt.nl/media/20458/elst-candidiasis-drugs-and-aging.pdf)

Dekkers BGJ, Veringa A, Marriott DJE, Boonstra JM, van der Elst KCM, Doukas FF, McLachlan AJ, Alffenaar JC.

Drugs Aging 2018 Sep;35(9):781-789